Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: ANRO )

12.58 -0.57 (-4.33%)
Official Closing Price Updated: 7:00 PM EDT, Jul 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 67,196
Open 13.19
Bid (Size) 4.000 (1)
Ask (Size) 33.00 (4)
Prev. Close 13.15
Today's Range 12.51 - 13.47
52wk Range 9.400 - 24.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
From Alto Neuroscience, Inc.
Via Business Wire

Performance

YTD
-39.23%
-39.23%
1 Month
+1.13%
+1.13%
3 Month
-10.53%
-10.53%
6 Month
-39.23%
-39.23%
1 Year
-39.23%
-39.23%

More News

Read More
Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On
Via InvestorPlace
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
From Alto Neuroscience, Inc.
Via Business Wire
ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024
Via InvestorPlace
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
From Alto Neuroscience, Inc.
Via Business Wire
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
Via Benzinga
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Alto Neuroscience, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Maker Of Wilson Tennis Rackets Raises $1.37 Billion In Discounted IPO
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.